Antibody Drug Conjugates for Cancer Therapy
Antibody Drug Conjugates for Cancer Therapy Antibody Drug Conjugates for Cancer Therapy
Structure of the MUC16 antigen and MAb binding sites.3A5 reacts with the mucin repeats that dominate the MUC16 sequence; 11D10recognizes a unique epitope in the extracellular domain.3A511D10TMH 2 N17 copies of mucin repeatCOOHFACS: OvCAR-3 Scatchard: OvCAR-3 Cell killing: OvCAR-311D103A5MAb(HuFcchimera)Affinity(pM)Sites percell11D10 52 31,7133A5 (#1) 433 243,4323A5 (#2) 288 107,760Cell viabilityArmed3A5Armed11D10Antibody amount
OvCAR3-luciferase intraperitoneal ovarian tumor modelDAY0 14 28 DAY 0 14 281.E+101.E+10Anti-Ragweedvc-MMAE11D10-vc-MMAE1.E+103A-5vc-MMAELuminescence1.E+081.E+061.E+041.E+081.E+061.E+041.E+081.E+061.E+041.E+020 7 14 21 28 35 42 49 56 63Daydosing at 2.5 mg/kg 1/wk x 4wk at d 0,7,14 and 211.E+021.E+020 7 14 21 28 35 42 49 56 63 0 7 14 21 28 35 42 49 56 63DayDay0/10 5/10
- Page 1 and 2: Antibody Drug Conjugates for Cancer
- Page 3: Target Screening- Large scale mRNA-
- Page 6 and 7: Naked antibodies are likely to be i
- Page 9 and 10: How many xenograft models should we
- Page 11 and 12: RelativeTenB2 expression in human p
- Page 13 and 14: Antibodies armed with auristatinsAN
- Page 15: MRP4 (multi drug resistance protein
- Page 20 and 21: Endothelin B receptor: A target for
- Page 22 and 23: Melanocytes and EDNBR staining in n
- Page 24 and 25: Increased cell killing in vitro wit
- Page 26 and 27: ETBR Expression in Cell Lines versu
- Page 28 and 29: Efficacy/SafetyFour ways for armed
- Page 30 and 31: Antibody doses are normalized to dr
- Page 32 and 33: In Vivo Efficacy is Retained With T
- Page 34 and 35: Cumulative toxicity from long-lived
- Page 36: • GNE ADC Team- Susan Spencer- Ke
Structure of the MUC16 antigen and MAb binding sites.3A5 reacts with the mucin repeats that dominate the MUC16 sequence; 11D10recognizes a unique epitope in the extracellular domain.3A511D10TMH 2 N17 copies of mucin repeatCOOHFACS: OvCAR-3 Scatchard: OvCAR-3 Cell killing: OvCAR-311D103A5MAb(HuFcchimera)Affinity(pM)Sites percell11D10 52 31,7133A5 (#1) 433 243,4323A5 (#2) 288 107,760Cell viabilityArmed3A5Armed11D10<strong>Antibody</strong> amount
Change language